The pharmaceutical giant GlaxoSmithKline (GSK) abandoned a maternal vaccine because there was an unexplained higher incidence of preterm birth among infants whose mothers received the shot, the company has disclosed in a new study.
Among women who received GSK’s respiratory syncytial virus (RSV) vaccine, known as RSVPreF3-Mat, during pregnancy, 237 had infants born prematurely. Just 89 in the placebo group suffered the same problem.
